Psychedelic-Assisted Therapy: Information & Education

    This page provides an educational overview of psychedelic-assisted therapy (PaT), including current research, safety considerations, legal context in Canada, preparation, integration, and contraindications. It is not a treatment advertisement or clinical guidance.

    For information on our clinical services, visit the Psychedelic-Assisted Therapy main page.

    Regulatory and Educational Context:

    Health Canada places strict limits on how psychedelic substances, outcomes, and clinical indications may be discussed in public-facing materials. For this reason, the information on this page is intentionally broad and focuses on education rather than clinical recommendations.

    Our goal is to provide helpful, understandable context while adhering to federal and provincial advertising standards for regulated health professionals. For personalized guidance, you are welcome to complete our screening questionnaire or connect with our team for further discussion.

    Woman meditating with eyes closed indoors during psychedelic-assisted therapy (PaT)

    Legal Status of Psychedelic Medicine in Canada

    The legal framework surrounding psychedelic medicine in Canada is evolving. Understanding this landscape helps individuals make informed decisions and differentiate between legal access, research contexts, and public education.

    Current Federal Regulations

    Most psychedelic substances are regulated under the Controlled Drugs and Substances Act (CDSA) and generally require federal authorization for medical use.

    However, certain medicines—such as those classified as dissociative anesthetics—may be legally used within community clinical settings when prescribed and administered by licensed practitioners operating within their professional scope.

    Legal access and regulatory oversight vary by substance, context, and the credentials of the prescribing clinician.

    Clinical Research Context

    Canada permits the use of several psychedelic substances in:

    • Federally approved clinical trials
    • Designated research environments
    • Specific exemption-based frameworks

    This page summarizes publicly available research and regulatory information. It does not imply that any particular substance is used or offered at our Centre unless explicitly indicated on our main service pages and delivered in accordance with medical scope and federal guidelines.

    Understanding Preparation (“Set and Setting”)

    Preparation is considered a central element of psychedelic-assisted therapeutic work across clinical research environments.

    Psychological Preparation

    Educational materials and guided exercises with a trained therapist emphasize:

    • Clarifying intentions
    • Exploring expectations
    • Developing emotion regulation and coping strategies
    • Strengthening inner resources and recruiting external support
    • Reviewing emotional safety practices

    Environmental Preparation (“Setting”)

    Research literature highlights the importance of:

    • A calm, supportive environment
    • Trusted therapeutic relationships
    • Consistent routines
    • Use of emotionally evocative music & eyeshades for deep inner exploration

    These elements help create conditions for reflective, meaningful inner experiences during clinical psychedelic-assisted work.

    Integration — Making Meaning After the Experience

    Integration refers to the process of making sense of insights, emotions, or themes that arise during psychedelic-assisted sessions within a therapeutic setting.

    What Integration Involves

    • Exploring emotional themes and building somatic self-awareness
    • Understanding and making meaning of symbolic or meaningful imagery
    • Relating insights to daily life
    • Strengthening adaptive patterns across a variety of life domains
    • Processing difficult feelings and building long-term resilience

      Why Integration Matters

      Academic literature consistently emphasizes integration as a major contributor to long-term personal growth following psychedelic therapy.

      This phase helps ensure that psychedelic-assisted experiences translate into practical, meaningful changes.

      Contraindications & Safety Considerations

      Psychedelic-assisted therapy—within any clinical or research setting—involves careful screening to reduce risk.

      Potential Medical Contraindications

      May include:

      • Certain cardiovascular conditions
      • Some neurological conditions
      • Pregnancy or breastfeeding
      • Unmanaged medical concerns

        Potential Psychological Contraindications

        Examples include:

        • Acute psychosis
        • Certain bipolar conditions
        • Severe instability or safety concerns
        • Active substance withdrawal or dependence
        • Some dissociative conditions

        These considerations are evaluated by regulated clinicians in contexts where psychedelic-assisted therapy is provided.

        Research & Evidence Summary

        This section summarizes peer-reviewed research in the field of psychedelic therapy without referencing specific substances, according to Health Canada restrictions.

        Areas of Investigation Include:

        • Trauma-informed psychedelic psychotherapy models
        • Emotional processing and reflective capacity
        • Meaning-making and existential exploration
        • Impacts on neuroplasticity and neuroconnectivity
        • Long-term follow-up outcomes
        • The role of preparation and integration
        • Safety monitoring and risk reduction strategies

        Research Landscape

        Psychedelic therapy is one of the fastest-growing areas of mental-health research worldwide, focusing on both:

        • Potential therapeutic applications and outcomes
        • Safety protocols and ethical frameworks

        Important Limitations

        • Findings may not generalize to all individuals
        • Research protocols may differ from community practice
        • Effects depend heavily on context, preparation, and integration
        • Psychedelic medicine is not appropriate for everyone

        This page provides public education, not clinical claims.

        Substances Discussed in Research

        This section does not imply that these substances are offered at our Centre. It explains commonly researched psychedelic medicines in global literature.

        Classic Psychedelic Substances

        Scientific and clinical research has examined several classic psychedelic substances in supervised or research-based settings.

        These studies explore themes such as:

        • Emotional processing and neural adaptability
        • Alterations in perception and consciousness
        • Introspection, meaning-making, and symbolic imagery
        • Safety protocols and structured therapeutic frameworks

        Below are examples of peer-reviewed research, provided solely for educational purposes. These citations do not imply that these substances are used or offered at our Centre.

        Tagliazucchi, E., Roseman, L., Kaelen, M., et al. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. Current biology, 26(8), 1043-1050.

        Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., et al. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853-4858

        Griffiths, R. R., Johnson, M. W., Carducci, M.A. et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology, 30(12), 1181-1197.

        Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283.

        Santos, G. H. D. M., Rodrigues, L. S., Rocha, J. M., et al. (2023). Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies. Psychoactives, 2(1), 76-91.

        Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016). Clinical applications of hallucinogens: A review. Experimental and clinical psychopharmacology, 24(4), 229.

        These citations are provided solely for educational purposes and do not imply the administration or availability of these substances at our Centre.

        Empathogen-Assisted Therapy

        Global research has examined empathogen-class substances in structured clinical and research environments. These studies have explored themes such as:

        • Therapeutic alliance and relational attunement within supportive settings
        • Emotional openness and reflective capacity
        • Trauma-informed processing models
        • Structured, supervised clinical protocols emphasizing safety and preparation

        Representative peer-reviewed research includes:

        • Mithoefer, M. C. (2011). Does MDMA have a role in clinical psychiatry?. Psychiatric Times, 28(5), 36-36.
        • Mitchell, J. M., Bogenschutz, M., Lilienstein, A., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033.
        • Mithoefer, M. C., Wagner, M. T., Mithoefer, A. et al. (2011). The safety and efficacy of±3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of psychopharmacology, 25(4), 439-452.
        • Smith, K. W., Sicignano, D. J., Hernandez, A. V. et al. (2022). MDMA‐assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review with meta‐analysis. The Journal of Clinical Pharmacology, 62(4), 463-471

        These citations are provided solely for educational purposes and do not imply the administration or availability of these substances at our Centre.

        Dissociative Medicines

        Research has also examined dissociative medicines in supervised clinical or academic settings. These studies focus on the structure, safety considerations, and therapeutic frameworks surrounding their use in regulated environments. Themes explored include:

        • Medically supervised administration protocols
        • Regulated prescriber oversight
        • Structured psychotherapeutic models used alongside experiential sessions
        • Safety, monitoring, and preparation practices in controlled environments

        Representative peer-reviewed research includes:

        • Feder, A., Costi, S., Rutter, S. B., et al. (2023). A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Focus, 21(3), 296-305
        • Park, L. T., Falodun, T. B., & Zarate Jr, C. A. (2019). Ketamine for treatment-resistant mood disorders. Focus, 17(1), 8-12.
        • Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134-1142.
        • Quintero, J. M., Bustos, R. H., Lechtig-Wassermann, S., Beltran, S., & Jr, C. (2025). Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic. CNS spectrums, 30(1), e51-, 1-16

          These references are offered solely for educational purposes and do not imply that dissociative medicines are available or administered at our Centre unless explicitly stated on our main service page within the scope of licensed practitioners.

          Further Reading & Academic Resources

          The following books, articles, and documentary films provide broader context on the history, cultural background, scientific inquiry, and evolving public understanding of psychedelic research. These materials are offered solely for public education and do not imply clinical use or endorsement of any specific substance or therapy model.

          Foundational Texts & Introductory Overviews

          • Pollan, M. (2018). How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. Penguin Press.
          • Metzner, R. (Ed.). (2005). Sacred vine of spirits: Ayahuasca. Inner Traditions/Bear & Co.
          • Strassman, R. (2001). DMT: The spirit molecule: A doctor’s revolutionary research into the biology of near-death and mystical experiences. Park Street Press.
          • Bache, C. M. (2019). LSD and the mind of the universe: Diamonds from heaven. Inner Traditions.
          • Grof, S., & Bennett, H. (1992). The holotropic mind: The three levels of human consciousness and how they shape our lives. HarperCollins.

            Documentary Films

            These documentary series explore the cultural, historical, and scientific context of psychedelic research and medicine:

            • Pollan, M. (Host). (2022). How to Change Your Mind [Documentary series]. Netflix.
               Explores the history, science, and cultural impact of psychedelic substances and their use in research and therapeutic settings.

            • In Waves and War (2024). Netflix Documentary.
               A documentary examining the emerging intersection of psychedelic research with trauma, psychological healing frameworks, and personal narratives.

            (Note: These materials are provided for general educational interest only and do not reflect or describe services offered by our Centre.)

            Scholarly & Professional Resources

            • Nichols, D.E (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355.
            • Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620.
            • Winkelman, M. J. (2017). The mechanisms of psychedelic visionary experiences: hypotheses from evolutionary psychology. Frontiers in Neuroscience, 11, 539.

            Classic Psychedelic Research & Consciousness Studies

            • Grof, S. (2015). Modern consciousness research and the understanding of art. In Presentation and book launching at the meeting of The Multidisciplinary Association for Psychedelic Studies (MAPS). San Francisco, CA.
            • Lampman, A. (2002). Hallucinogens: A Reader. Anthropology of Consciousness, 13(2), 64-65.
            • Doblin, R. (1991). Pahnke’s “Good Friday Experiment” – A Long-Term Follow-Up and Methodological Critique. Cambridge, Massachusetts.

            Cross-Cultural & Anthropological Perspectives

            • Labate, B. C., Cavnar, C., & Gearin, A. K. (Eds.). (2016). The world ayahuasca diaspora: Reinventions and controversies. Taylor & Francis.
            • Harner, M., & Harner, S. (2000). Core practices in the shamanic treatment of illness. Shamanism, 13(1-2), 19-30.

            Neuroscience & Psychological Mechanisms

            • Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological reviews, 71(3), 316-344.
            • Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642-651.

            This page is educational only. It does not indicate availability of specific substances.

            Limitations of Psychedelic-Assisted Therapy

            Understanding limitations helps set realistic expectations and supports safe decision-making.

            What PaT Cannot Do

            • It is not an automatic cure or quick-fix solution
            • It cannot replace long-term therapeutic work
            • It is not suitable for crisis stabilization
            • It cannot guarantee insight or emotional resolution
            • It may not be appropriate for certain mental-health conditions

              Factors That Influence Outcomes

              • Client readiness
              • Psychological stability
              • Quality of preparation
              • Therapeutic relationship
              • Integration practice

              Important Disclaimer

              This page is for educational purposes only. It does not describe the effects, benefits, or outcomes of controlled substances, nor does it constitute medical advice, psychotherapy, or a guarantee of eligibility for any treatment.

              All clinical services are delivered by licensed prescribers and regulated health professionals in accordance with Health Canada and provincial standards.

              Educational FAQ — Psychedelic-Assisted Therapy

              Is psychedelic-assisted therapy legal in Canada?

              Psychedelic medicine is regulated under federal law. Certain contexts—such as research trials, use of specific legal substances (such as dissociative anesthetics) in community clinics, or specific authorization pathways—permit supervised use.

              Is psychedelic-assisted therapy safe?

              Psychedelic-assisted therapy can be very safe under the right conditions.  However, safety depends heavily on professional screening, medical oversight, environment, preparation, integration, and clinician training.

              What substances are discussed in research?

              Global research examines several categories of psychedelic medicine, including “classic psychedelics”, “empathogens”, and “dissociative anesthetics”. This information is provided for education only.

              How do people prepare for psychedelic therapy?

              Preparation involves guided intention-setting, emotional readiness, developing emotion regulation and grounding skills, and establishing a supportive therapeutic environment.

              What is integration?

              Integration refers to making meaning from the experience and weaving insights into daily life to promote lasting personal growth through psychotherapeutic support.

              How do I know if PaT is appropriate for me?

              Eligibility must be determined through a formal clinical assessment, as outlined on our main PaT service page.

              Want to Learn About Our Clinical PaT Services?

              Visit the Psychedelic-Assisted Therapy main page for an overview of our clinical process, safety and eligibility screening, service details, our team and approach, and discovery call information. This info page is strictly educational. For service inquiries, please contact us directly.

              MLC Blog

              Two Mindful Tools for Managing Irritability

              Two Mindful Tools for Managing Irritability

              Irritability often begins in the body before it shows up in behaviour. Slow breathing and progressive muscle relaxation are two mindful tools that help calm the nervous system so you can respond with clarity instead of reactivity.

              read more
              Developing a Game Plan for Irritability

              Developing a Game Plan for Irritability

              You can’t prevent every moment of irritability—but you can prepare for it. Developing a game plan gives you tools to rely on before and during difficult moments, helping you respond with clarity rather than reactivity.

              read more
              See additional blogs

              Individual Therapy

              COUPLE Therapy

              Psycho-Educational Assessments

              Child and Family Therapy